Valiltramiprosate is an investigational new drug that is being evaluated to treat early Alzheimer's disease.[1] It is an amyloid precursor protein antagonist.[2]
Clinical data | |
---|---|
Other names | ALZ-801; BLU8499 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C8H18N2O4S |
Molar mass | 238.30 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ "Valiltramiprosate - Alzheon". AdisInsight. Springer Nature Switzerland AG.
- ^ Lee D, Antonsdottir IM, Clark ED, Porsteinsson AP (May 2024). "Review of valiltramiprosate (ALZ-801) for the treatment of Alzheimer's disease: a novel small molecule with disease modifying potential". Expert Opinion on Pharmacotherapy. 25 (7): 791–799. doi:10.1080/14656566.2024.2360069. PMID 38814590.